Date: October 09, 2026

Board Meeting Outcomes

  • The company received a corrected In-principle Approval letter from BSE Limited (letter no. LOD/PREF/PB/FIP/908/2026-27) dated October 07, 2026, rectifying factual errors in the earlier approval letter
  • The approval is for the issue of 16,21,000 warrants convertible into 16,21,000 Equity shares of face value ₹5 each at an issue price of ₹566 each to the Promoter and Promoter Group of the Company on preferential basis
  • This is in continuation of the company's intimation dated October 08, 2026 (Ref. No. KDL/SE/053/2026-27) regarding receipt of In-principle Approval from both BSE Limited and National Stock Exchange of India Limited

Regulatory Compliance Requirements

  • The company must ensure issue and allotment complies with Companies Act 2013, SCRA 1956, SEBI Act 1992, Depositories Act 1996, SEBI ICDR Regulations 2018, and SEBI LODR Regulations 2015
  • The company is advised to strengthen internal controls to monitor trades executed by proposed allottees in the company's scrip before allotment
  • Must obtain undertaking from allottees confirming they: a) shall not do intra-day trading in the company scrip or any sale till the allotment date, b) understand the responsibility is solely on the issuer company to verify compliance
  • Any non-compliances observed post-undertaking may impact the listing of such shares
  • Company must make listing application without delay after allotment with applicable fees under Regulation 14 of LODR Regulations
  • Must apply for listing within twenty days from date of allotment as per SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023
  • BSE reserves right to withdraw approval if information is found incomplete/incorrect/misleading/false or contravenes any regulations

Additional Information

  • The approval should not be construed as approval for listing of the security
  • Company must obtain all statutory and other required approvals
  • Depositories will automatically release excess lock-in period of Pre-Preferential Holding of allottees without requiring NOC from Exchange
  • The information is available on company website: https://krsnaadiagnostics.com/investors/